David Freund

David Freund

Auto-generated profile, based on publicly available information

David Freund

Tempest Therapeutics, Brisbane, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
BFBrian J. Francica
Brian J. Francica
AHAnja Holtz
Anja Holtz
JLJustine M Lopez
Justine M Lopez
DFDavid Freund
David Freund
ACAustin Chen
Austin Chen
TDThomas W. Dubensky
Thomas W. Dubensky
While the role of prostaglandin E2 (PGE2) in promoting malignant progression is well established, how to optimally block the activity of PGE2 signaling remains to be demonstrated. Clinical trials with prostaglandin pathway targeted agents have shown activity but without sufficient significance or dose-limiting toxicities that have prevented approval. PGE2 signals through four receptors (EP1–4) to modulate tumor progression. EP2 and EP4 signaling exacerbates tumor pathology and is immunosuppressive through potentiating cAMP production. EP1 and EP3 signaling has the opposite effect through increasing IP3 and decreasing cAMP. Using available small-molecule antagonists of single EP receptors, the cyclooxygenase-2 (COX-2) inhibitor celecoxib, or a novel dual EP2/EP4 antagonist generated in this investigation, we tested which approach to block PGE2 signaling optimally restored immunologic activity in mouse and human immune cells and antitumor activity in syngeneic, spontaneous, and xenograft tumor models. We found that dual antagonism of EP2 and EP4 together significantly enhanced the activation of PGE2-suppressed mouse and human monocytes and CD8+ T cells in vitro as compared with single EP antagonists. CD8+ T-cell activation was dampened by single EP1 and EP3 antagonists. Dual EP2/EP4 PGE2 receptor antagonists increased tumor microenvironment lymphocyte infiltration and significantly reduced disease burden in multiple tumor models, including in the adenomatous polyposis coli (APC)min+/− spontaneous colorectal tumor model, compared with celecoxib. These results support a hypothesis that redundancy of EP2 and EP4 receptor signaling necessitates a therapeutic strategy of dual blockade of EP2 and EP4. Here we describe TPST-1495, a first-in-class orally available small-molecule dual EP2/EP4 antagonist. Significance: Prostaglandin (PGE2) drives tumor progression but the pathway has not been effectively drugged. We demonstrate significantly enhanced immunologic potency and antitumor activity through blockade of EP2 and EP4 PGE2 receptor signaling together with a single molecule.

8 August 2023
Verified
Other
Open access
BFBrian J. Francica
Brian J. Francica
AHAnja Holtz
Anja Holtz
JLJustine Lopez
Justine Lopez
DFDavid Freund
David Freund
ACAustin Chen
Austin Chen
TDThomas W. Dubensky
Thomas W. Dubensky
TPST-1495 exhibits immune-independent antitumor activity. CT26 tumor longitudinal outgrowth of WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 BID for 2 weeks (A) and day 14 volumetric comparisons between mouse groups (B). Results are representative of three experiments with at least 8 mice per experiment. CT26 tumor longitudinal outgrowth (C) and day 14 volumetric comparisons (D and E) in WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 twice a day for 2 weeks and 10 μL anti-asialo-GM1 antibody. F, Experimental schematic of LS174T colorectal xenograft model and tumor growth results. G, Enumeration of tumor burden by primary tumor weight, metastatic organ weight, or count of metastatic nodules. Results are representative of two experiments with at least 8 mice per experiment. Mean and SD are depicted in all graphs and the Student two-sided t test was used to assess significance between individual groups. ns, not significant; ***, P < 0.001; **, P < 0.01; *, P < 0.05.

13 July 2023
Verified
Other
Open access
BFBrian J. Francica
Brian J. Francica
AHAnja Holtz
Anja Holtz
JLJustine M Lopez
Justine M Lopez
DFDavid Freund
David Freund
ACAustin Chen
Austin Chen
TDThomas W Dubensky
Thomas W Dubensky
TPST-1495 Displays T cell-independent anti-tumor efficacy in CT26.

13 July 2023
Verified
Other
Open access
BFBrian J. Francica
Brian J. Francica
AHAnja Holtz
Anja Holtz
JLJustine M Lopez
Justine M Lopez
DFDavid Freund
David Freund
ACAustin Chen
Austin Chen
TDThomas W Dubensky
Thomas W Dubensky
Increased efficacy with TPST-1495 and α-PD-1 combination therapy in CT26 model.

13 July 2023
Verified
Other
Open access
BFBrian J. Francica
Brian J. Francica
AHAnja Holtz
Anja Holtz
JLJustine M Lopez
Justine M Lopez
DFDavid Freund
David Freund
ACAustin Chen
Austin Chen
TDThomas W Dubensky
Thomas W Dubensky
TPST-1495 EP receptor antagonist activity and specificity